Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 28:2:101895.
doi: 10.1016/j.gimo.2024.101895. eCollection 2024.

Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans

Michael R Sargen  1 , Jung Kim  1 , Jeremy S Haley  2 , Hayley P Barker  3 , Piyushkumar A Mundra  3   4 , Mandy L Ballinger  3   4   5 , David M Thomas  3   6 , David J Carey  2 , Alisa M Goldstein  1 , Douglas R Stewart  1
Affiliations

Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans

Michael R Sargen et al. Genet Med Open. .

Abstract

Purpose: To identify candidate susceptibility genes for dermatofibrosarcoma protuberans (DFSP).

Methods: All individuals with DFSP from the International Sarcoma Kindred Study (n = 3767 individuals with sarcoma diagnoses from Australia, Europe, New Zealand, and United States) and cohorts that were not ascertained based on sarcoma status or other phenotypes (Geisinger MyCode, n = 170,503 individuals, United States; UK Biobank, n = 469,789 individuals, United Kingdom) were evaluated for germline pathogenic or likely pathogenic (P/LP) variants in 156 cancer genes.

Results: There were 92 unrelated individuals with DFSP across the 3 cohorts. The mean age at diagnosis (standard deviation) in the International Sarcoma Kindred Study, Geisinger, and UK Biobank was 40.8 (14.5), 50.3 (9.4), and 49.4 (13.2) years, respectively. Germline P/LP variants were most common in the CHEK2 gene (4/92 [4.3%]). CHEK2-related cases were often associated with early onset disease (age at diagnosis: 30-39 years) and were observed in all 3 cohorts. Among 640,292 individuals in Geisinger and UK Biobank who were not ascertained based on phenotype, there was a significantly increased frequency of CHEK2 P/LP variants among individuals with DFSP (n = 3/65 [4.6%]) compared to those without (n = 6388/640,227 [1.0%]) (Fisher exact, P = .03). Additional genes with P/LP variation (1 case for each gene) included ACD, ERCC5, ERCC1, DOCK8, GBA1, ATM, MUTYH, TP53, RECQL4, and COL7A1.

Conclusion: This study of multiple cohorts identifies CHEK2 as a candidate susceptibility gene for DFSP. Additional epidemiologic and functional studies are needed to further characterize this potential gene-tumor relationship.

Keywords: CHEK2; Cancer predisposition; Dermatofibrosarcoma protuberans; Sarcoma; Skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Kreicher K.L., Kurlander D.E., Gittleman H.R., Barnholtz-Sloan J.S., Bordeaux J.S. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(suppl 1):S24–S31. doi: 10.1097/DSS.0000000000000300. - DOI - PubMed
    1. David M.P., Funderburg A., Selig J.P., et al. Perspectives of patients with dermatofibrosarcoma protuberans on diagnostic delays, surgical outcomes, and nonprotuberance. JAMA Netw Open. 2019;2(8) doi: 10.1001/jamanetworkopen.2019.10413. - DOI - PMC - PubMed
    1. Gardner T.L., Elston D.M., Wotowic P.J. A familial dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1998;39(3):504–505. doi: 10.1016/s0190-9622(98)70338-x. - DOI - PubMed
    1. Marre D., Redondo P., Vicente J. Familial dermatofibrosarcoma protuberans: a nonfortuitous association? Dermatol Surg. 2013;39(5):820–821. doi: 10.1111/dsu.12187. - DOI - PubMed
    1. Kesserwan C., Sokolic R., Cowen E.W., et al. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol. 2012;129(3):762–769.e1. doi: 10.1016/j.jaci.2011.10.028. - DOI - PMC - PubMed